ES2174833T3 - Fosfolipidos. - Google Patents

Fosfolipidos.

Info

Publication number
ES2174833T3
ES2174833T3 ES92911596T ES92911596T ES2174833T3 ES 2174833 T3 ES2174833 T3 ES 2174833T3 ES 92911596 T ES92911596 T ES 92911596T ES 92911596 T ES92911596 T ES 92911596T ES 2174833 T3 ES2174833 T3 ES 2174833T3
Authority
ES
Spain
Prior art keywords
pct
dha
epa
fatty acids
phospholipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911596T
Other languages
English (en)
Inventor
Carin Larsson-Backstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi AB
Original Assignee
Fresenius Kabi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi AB filed Critical Fresenius Kabi AB
Application granted granted Critical
Publication of ES2174833T3 publication Critical patent/ES2174833T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION ES RELATIVA A UNA EMULSION QUE COMPRENDE FOSFOLIPIDOS QUE CONTIENEN OMEGA-3-ACIDOS GRASOS TALES COMO DHA Y EPA EN UNA ELEVADA CANTIDAD Y UN ACEITE VEGETAL Y/O ACEITE MARINO. TAMBIEN ES RELATIVO AL USO DE FOSFOLIPIDOS QUE CONTIENEN LOS OMEGA-3- ACIDOS GRASOS TALES COMO DHA Y EPA EN ELEVADAS CANTIDADES PARA LA FABRICACION DE UNA EMULSION NUTRITIVA QUE DA BAJOS NIVELES DE TRIGLICERIDO Y COLESTEROL EN SUERO, Y A LA FABRICACION DE UN MEDICAMENTO CON EFECTOS ANTI-INFLAMATORIOS E INMUNOSUPRESORES. LA INVENCION TAMBIEN DESCRIBE FOSFOLIPIDOS QUE CONTIENEN OMEGA-3- ACIDOS GRASOS TALES COMO DHA Y EPA CON EFECTOS TERAPEUTICOS TALES COMO EFECTOS SOBRE CELULAS ACTIVAS INFLAMATORIAMENTE E INMUNOLOGICAMENTE, P. EJ. ARTRITIS REUMATICA Y SEPSIA, Y UN EFECTO SOBRE DESARROLLO Y FUNCION NORMAL DE CEREBRO Y RETINA Y ENFERMEDADES CARDIOVASCULARES. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y NUTRITIVAS ASI COMO PARTICULAS LIPIDAS QUE COMPRENDEN LOS FOSFOLIPIDOS.
ES92911596T 1991-05-30 1992-05-19 Fosfolipidos. Expired - Lifetime ES2174833T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101642A SE9101642D0 (sv) 1991-05-30 1991-05-30 Phospholipids

Publications (1)

Publication Number Publication Date
ES2174833T3 true ES2174833T3 (es) 2002-11-16

Family

ID=20382886

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911596T Expired - Lifetime ES2174833T3 (es) 1991-05-30 1992-05-19 Fosfolipidos.

Country Status (14)

Country Link
US (1) US5434183A (es)
EP (1) EP0660708B1 (es)
JP (1) JP3387498B2 (es)
AT (1) ATE216227T1 (es)
AU (1) AU657969B2 (es)
CA (1) CA2109611A1 (es)
DE (1) DE69232564T2 (es)
ES (1) ES2174833T3 (es)
IE (1) IE921477A1 (es)
NZ (1) NZ242697A (es)
PT (1) PT100524B (es)
SE (1) SE9101642D0 (es)
SG (1) SG64864A1 (es)
WO (1) WO1992021335A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277557A1 (es) * 2005-12-21 2007-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
WO1994022313A1 (en) * 1993-04-01 1994-10-13 Ici Australia Operations Proprietary Limited Pan release agent
WO1994028732A1 (en) * 1993-06-07 1994-12-22 Ici Australia Operations Proprietary Limited Reduction of moisture loss from plant and animal matter
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
DK0784437T3 (da) * 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
DE69612011T3 (de) * 1995-11-24 2010-02-18 Unilever N.V. Zusammensetzung auf basis von fischöl
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
DE19644518A1 (de) * 1996-10-25 1998-04-30 Nutricia Nv Wässrige Fettemulsion, diese enthaltende Nahrung und deren Verwendung
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) * 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US5955102A (en) 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
CO5150202A1 (es) 1998-12-31 2002-04-29 Kimberly Clark Co Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DE60123603T2 (de) * 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
US20020155161A1 (en) * 2000-12-29 2002-10-24 Deckelbaum Richard J. Use of IV emulsions with different triglyceride composition, particle size and apolipoprotein E for targeted tissue delivery of hydrophobic compounds
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
WO2003017945A2 (en) * 2001-08-24 2003-03-06 Martek Biosciences Boulder Corporation Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum
EP1489915A4 (en) * 2002-03-08 2005-09-14 Monsanto Technology Llc TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
US20060128665A1 (en) * 2002-11-26 2006-06-15 Phares Pharmaceutical Research N.V. Marine lipid compositions
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
EP1684739A4 (en) * 2003-11-12 2006-12-06 Childrens Medical Center TREATMENT AND PREVENTION OF LIVER DISEASES RELATED TO PARENTERAL DIET (PN)
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US20050281926A1 (en) * 2004-06-10 2005-12-22 Kellogg Company Topical application of marine oils to food
JP5667737B2 (ja) * 2004-07-01 2015-02-12 ネステク ソシエテ アノニム イヌ変形性関節症食餌製剤
EP1811867A2 (en) * 2004-11-12 2007-08-01 N.V. Nutricia Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses
FR2880538B1 (fr) * 2005-01-07 2008-12-26 Polaris Soc Par Actions Simpli Composition cosmetique et cosmeceutique a base d'huiles de poissons, de phospholipides d'origine marine avec ou sans huile de pepins de franboise
GB0506788D0 (en) * 2005-04-04 2005-05-11 Biosea Man As Process
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
US9265745B2 (en) * 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods
WO2008149177A2 (en) * 2006-05-05 2008-12-11 Natural Asa Marine lipid compositions and uses thereof
US20080044487A1 (en) 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
WO2008143642A2 (en) * 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
US20090018870A1 (en) * 2006-12-01 2009-01-15 Joseph Thomas Weishaar Method for Preventing Chronic Disease
JP5485704B2 (ja) 2007-02-15 2014-05-07 シュ サント−ジュスティーヌ 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
PL2144618T5 (pl) 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
JP5426530B2 (ja) * 2007-03-30 2014-02-26 シュ サント−ジュスティーヌ 脊柱側弯症の危険性の決定方法
US20110065673A1 (en) * 2007-05-11 2011-03-17 Bizen Chemical Co., Ltd. Novel leukotriene receptor agonist
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090061067A1 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa Method for making krill meal
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
RU2505292C2 (ru) 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения гипертриглицеридемии
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NO333013B1 (no) * 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP3335713B1 (en) 2009-10-29 2022-08-31 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
WO2011091160A1 (en) * 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US12635720B2 (en) 2011-04-17 2026-05-26 Omega Foods Llc Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN103608023A (zh) * 2011-06-15 2014-02-26 稳定解决方案有限责任公司 磷虾油的胃肠外治疗应用
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150110866A1 (en) * 2012-05-22 2015-04-23 Harold Gordon Cave Complexes and compositions containing curcumin
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CA2883997C (en) 2012-08-29 2021-02-16 Universite Du Quebec A Chicoutimi Dihydrochalcone derivatives and their use as antibiotic agents
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
AU2014284075A1 (en) 2013-06-17 2016-01-07 Chu Sainte-Justine Gi protein phosphorylation as marker for scoliosis and scoliosis progression, methods of increasing GiPCR signaling in scoliotic subjects
KR20160020554A (ko) 2013-06-17 2016-02-23 슈 생-쥐스땡 척추측만 개체의 세포에서 gipcr 신호전달을 증가시키는 방법
KR20160020553A (ko) 2013-06-17 2016-02-23 슈 생-쥐스땡 특발성 척추측만증의 심각한 진행에 대한 새로운 마커, 그리고 척추측만 환자를 층화하고 척추측만증이 발달할 위험을 예측하기 위한 이들의 용도
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
EP3024471B1 (en) 2013-07-22 2019-10-30 Université du Québec à Chicoutimi Use of plant extracts against herpes simplex virus
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
BR112017005388B1 (pt) 2014-10-02 2022-09-13 Evonik Operations Gmbh Alimento para animais contendo biomassa de aurantiochytrium
CN106793803B (zh) 2014-10-02 2021-03-09 赢创运营有限公司 通过挤压含pufa的生物质来制备含pufa的饲料的方法
CA2958439C (en) 2014-10-02 2022-09-20 Evonik Industries Ag Feedstuff of high abrasion resistance and good stability in water, containing pufas
CN107075540A (zh) 2014-10-02 2017-08-18 赢创德固赛有限公司 用于制备具有高细胞稳定性的含pufa生物质的方法
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
ES2866051T3 (es) * 2015-03-19 2021-10-19 Arctic Nutrition As Métodos para obtener fosfolípidos y composiciones de los mismos
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP3630740B1 (en) 2017-05-25 2026-07-01 The Governors of the University of Alberta SPECIFIC HUMAN NEURAMINIDASE ISOENZYME INHIBITORS USED IN THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
US11324697B2 (en) 2017-08-10 2022-05-10 The Children's Medical Center Corporation Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN109527123A (zh) * 2018-12-14 2019-03-29 大连大学 一种对慢性肠炎具有改善作用的调和油
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
JP2025531817A (ja) 2022-09-14 2025-09-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 動物に健康上の効果を提供するための南洋サバ油を利用した組成物及び方法
JP7886478B1 (ja) * 2025-10-16 2026-07-07 Ｕｍｉｏｓ株式会社 乳化用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT333437B (de) * 1974-02-07 1976-11-25 Etapharm Chem Pharm Lab Ges M Verfahren zur herstellung von phosphatidkomplexen mit erhohtem phosphatidylathanolamingehalt aus tierischem material
DE3347269A1 (de) * 1983-12-28 1985-07-11 Pearson & Co (GmbH & Co), 5000 Köln Pharmazeutisch wirksame lecithine mit polyungesaettigten fettsaeuren
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277557A1 (es) * 2005-12-21 2007-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.

Also Published As

Publication number Publication date
JP3387498B2 (ja) 2003-03-17
JPH06508123A (ja) 1994-09-14
CA2109611A1 (en) 1992-12-10
DE69232564D1 (de) 2002-05-23
IE921477A1 (en) 1992-12-02
PT100524A (pt) 1993-08-31
SG64864A1 (en) 2001-01-16
EP0660708B1 (en) 2002-04-17
WO1992021335A1 (en) 1992-12-10
AU657969B2 (en) 1995-03-30
US5434183A (en) 1995-07-18
NZ242697A (en) 1994-02-25
PT100524B (pt) 1999-08-31
AU1910192A (en) 1993-01-08
SE9101642D0 (sv) 1991-05-30
ATE216227T1 (de) 2002-05-15
DE69232564T2 (de) 2002-09-26
EP0660708A1 (en) 1995-07-05

Similar Documents

Publication Publication Date Title
SE9101642D0 (sv) Phospholipids
EP1041896B1 (de) Fettmischung und dieselben enthaltendes diäteisches oder pharmazeutisches mittel
Kremer n− 3 Fatty acid supplements in rheumatoid arthritis
Childs et al. The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects
DE3172223D1 (en) Edible, pharmaceutical compositions and processes for making thereof
NO940277L (no) Triglycerider og blandinger av slike
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
KR970704433A (ko) 의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition)
PT956013E (pt) Preparacao farmaceutica compreendendo acido eicosapentaenoico e/ou acido estearidonico
JPH07502491A (ja) 皮膚疾患の治療に対して静脈的に投与される薬剤を調整するためのエマルジョンの使用
KR880008797A (ko) 실리마린이 포함된 피부미용용 조성물
DK68080A (da) Anvendelse af fuldstaendigt acetylerede monoglycerider til saenkning af forhoejede cholesterinspejl og eller neutralfedtspejl i menneskeblod
CA2189202A1 (en) Stable Edible Oil Composition
ATE258792T1 (de) Diät mit hohem lipidgehalt
DK0784437T3 (da) Phospholipidholdig fedtblanding med LCP-fedtsyrer
DK0456764T3 (da) Omega-3-fedtsyreholdig fedtemulsion til endotracheal indgift, fremstilling og anvendelse heraf
CA2124605A1 (en) Prevention and improvement of medical symptoms caused by leucotriene b4
US5922345A (en) Nutrition
ATE121592T1 (de) Nicht-temperiertes fett für süsswaren.
Carlson The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man
US4999380A (en) Treatment of lipoprotein disorders associated with cholesterol metabolism
NO950621L (no) Fiskefor
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
Rao et al. Dietary carbohydrate stimulates alcohol diet ingestion, promotes growth and prevents fatty liver in rats
CA1314229C (en) Treatment of lipoprotein disorders associated with cholesterol metabolism

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 660708

Country of ref document: ES